Evidence map›Paper›PMID 38155632›Full record

ArticleNagoya journal of medical science2023

An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile.

Yoshiki Sato, Shoichi Deguchi, Tomoko Norose, Takuma Oishi, Koichi Mitsuya, Takashi Sugino, Yasuto Akiyama, Takeshi Nagashima, Kenichi Urakami, Yuji Shimoda and 3 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Nagoya journal of medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yoshiki SatoDivision of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Shoichi DeguchiDivision of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Tomoko NoroseDivision of Diagnostic Pathology, Shizuoka Cancer Center, Nagaizumi, Japan.
Takuma OishiDivision of Diagnostic Pathology, Shizuoka Cancer Center, Nagaizumi, Japan.
Koichi MitsuyaDivision of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Takashi SuginoDivision of Diagnostic Pathology, Shizuoka Cancer Center, Nagaizumi, Japan.
Yasuto AkiyamaDivision of Immunotherapy, Shizuoka Cancer Center, Nagaizumi, Japan.
Takeshi NagashimaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Nagaizumi, Japan.
Kenichi UrakamiMedical Genetics Division, Shizuoka Cancer Center Research Institute, Nagaizumi, Japan.
Yuji ShimodaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Nagaizumi, Japan.
Keiichi OhshimaMedical Genetics Division, Shizuoka Cancer Center Research Institute, Nagaizumi, Japan.
Nakamasa HayashiDivision of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Ken YamaguchiShizuoka Cancer Center, Nagaizumi, Japan.
Shizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliosarcoma (GS), a morphological variant of glioblastoma, pathologically shows a biphasic pattern with gliomatous and sarcomatous components. It has been reported that GS has much higher metastatic capacity than glioblastoma. A few reports on the pathology of the extracranial metastasis of GS have shown that metastatic lesions had a sarcomatous component alone or a mixture of gliomatous and sarcomatous ones. Therefore, it is considered that GS tends to disseminate hematogenously due to its mesenchymal sarcomatous component. Herein, we report an autopsy case of GS with multiple extracranial metastases treated by craniotomy, radiotherapy, and bevacizumab. In this case, metastatic lesions at autopsy contained a gliomatous component alone, but no sarcomatous component. In addition, the sarcomatous component disappeared from the intracranial lesion at autopsy after the administration of bevacizumab. In this report, we discuss the clinical course and pathological findings at the initial state, recurrence, and autopsy, including the results of whole-genome analysis.

Indexed as

Brain NeoplasmsGlioblastomaGliosarcomaBevacizumabGenetic ProfileHumansBevacizumabbevacizumabgliosarcomametastasispathologywhole-genome analysis

Identifiers

PMID38155632
PMCPMC10751501
OpenAlexW4390418756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.